Will kinase inhibitors have a dark side?
Sawyers
Charles L
CL
Department of Medicine, University of California, Los Angeles, Los Angeles, USA.
D000818:Animals; D014408:Biomarkers, Tumor; D006801:Humans; D051379:Mice; D009154:Mutation; D009362:Neoplasm Metastasis / Q000503:physiopathology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology
D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D018719:Erb-b2 Receptor Tyrosine Kinases